The assessment of changes in macular thickness in diabetic and non-diabetic patients: the effect of topical ketorolac on macular thickness change after ND:YAG laser capsulotomy

• Published in: Cutaneous and ocular toxicology 2016-01, Vol.35 (1), p.58-61
• Main Authors: Yılmaz, Uğur, Küçük, Erkut, Ulusoy, Döndü Melek, Özköse, Ayşe, Ataş, Mustafa, Demircan, Süleyman, Yuvacı, Isa
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Capsule Opacification - drug therapy; Capsule Opacification - therapy; Capsulotomy; Diabetes Mellitus - drug therapy; Diabetes Mellitus - pathology; Female; Humans; ketorolac; Ketorolac - therapeutic use; Lasers, Solid-State; Macula Lutea - drug effects; Macula Lutea - pathology; Male; Middle Aged; Nd:YAG laser; posterior capsule opacification; Posterior Capsulotomy - adverse effects
• ISSN: 1556-9527; 1556-9535
• DOI: 10.3109/15569527.2015.1017579

Purpose: The purpose of our study is to assess the changes in macular thickness (MT) in diabetic and non-diabetic patients and to research effects of topical ketorolac (Acular®, Allergan, Irvine, CA) on MT change after neodymium:yttrium aluminum garnet (Nd:YAG) laser capsulotomy. Material and methods: This study involved 88 eyes of 88 patients diagnosed as posterior capsule opacification (PCO). Patients were divided into four groups according to presence of diabetes mellitus (DM) and drugs used after capsulotomy. Group 1: Patients with DM using only 0.1% Fluorometholon (FML®, Allergan, Irvine, CA) after capsulotomy (22 patients). Group 2: Patients with DM using 0.5% ketorolac (Acular®) and 0.1 Fluorometholon (FML®, Allergan, Irvine, CA) after capsulotomy (20 patients). Group 3: Patients without DM using only 0.1% Fluorometholon (FML®, Allergan, Irvine, CA) (22 patients). Group 4: Patients without DM using 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®, Allergan, Irvine, CA) (24 patients). A plus-shaped capsulotomy was performed using VISULAS® YAGIII (Carl Zeiss) laser microscope. MT measurement with Cirrus SD-OCT (Carl Zeiss Opthalmic System Inc., Model 400, Dublin, CA, Software 5) were done. Measurements were done before laser, and on the first day, first week, first month, third month and sixth month after laser capsulotomy. We compared the four groups for MT change during 6 months. Results: Group 1 involving patients with DM using only 0.1% Fluorometholon (FML®, Allergan, Irvine, CA) after capsulotomy had increased MT at the first week, and the first, third, and sixth month after laser (p  0.05). There was no statistically significant increase in MT during the follow-up period in group 2 involving patients with DM using 0.5% ketorolac (Acular®) and 0.1 Fluorometholon (FML®, Allergan, Irvine, CA) after capsulotomy and group 4 involving patients without DM using 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®, Allergan, Irvine, CA) (p > 0.05). Conclusion: An increase in MT can be observed after Nd:YAG laser capsulotomy, especially in diabetic patients. Adding topical ketorolac (Acular®, Allergan, Irvine, CA) to topical Fluorometholon (FML®, Allergan, Irvine, CA) therapy after YAG laser capsulot